Search Results

You are looking at 1 - 10 of 268 items for :

Clear All
Full access

Komal Jhaveri and Francisco J. Esteva

trastuzumab resulting in enhanced blockade of the HER signaling pathway Evaluate the safety and efficacy of pertuzumab in the management of HER2 + breast cancer in the neoadjuvant and metastatic settings Background Approximately 20% of breast

Full access

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein and Yanis Boumber

currently approved for ALK-positive patients in the second-line setting. 2 Similarly, first-line treatment of breast carcinomas with amplification of ERBB2 ( HER2 ) includes trastuzumab and pertuzumab, whereas in the second-line setting, ado

Full access

Ahmad Hamad, Aatur D. Singhi, Nathan Bahary, Kevin McGrath, Rula Amarin, Herbert J. Zeh and Amer H. Zureikat

results. 3 Overexpression of the HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn and Alan P. Venook

H ER2 gene amplifications and activating mutations in the HER2 receptor tyrosine kinase are present in 4% of metastatic colorectal cancers (mCRCs). HER2-targeted therapy is not standard of care, although preclinical and clinical data suggest that

Full access

Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough and Daniel V.T. Catenacci

Background Patients with metastatic or locally advanced gastroesophageal cancer whose tumors overexpress the HER2 protein are eligible to receive the HER2-targeted therapy trastuzumab. 1 The expectation for trastuzumab or any other biomarker

Full access

William J. Gradishar

Since ErbB2 (HER2) was first recognized in the 1980s as an oncogenic driver of breast cancer, treatment of patients with HER2 overexpression has advanced at a steady pace. Recognition has also grown that HER2-positive disease is heterogeneous, and

Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans and Cary P. Gross

, well-differentiated invasive ductal carcinoma, ER-positive, HER2-negative, without lymph node involvement. Her medical oncologist used the PREDICT tool to estimate benefits of chemotherapy: the 10-year overall survival would be 88.1% with adjuvant

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma and Matthew J. Ellis

Breast cancer genome sequencing has identified HER2 -activating mutations in cancers that are HER2 -negative by immunohistochemistry or fluorescence in situ hybridization. 1 , 2 These HER2-activating mutations cause an oncogenic transformation

Full access

Saranya Chumsri, Jodi Weidler, Siraj Ali, Sohail Balasubramanian, Gerald Wallweber, Lisa DeFazio-Eli, Ahmed Chenna, Weidong Huang, Angela DeRidder, Lindsay Goicocheal and Edith A. Perez

initially positive for estrogen (ER) and progesterone receptor (PR), but HER2-negative (1+) by immunohistochemistry (IHC). At that time, she underwent left lumpectomy with sentinel lymph node biopsy, which revealed a 5-cm moderately differentiated grade 2

Full access

Arif H. Kamal, Steve Power, Gloria Broadwater, Audrey R. Holland and Paul K. Marcom

with patient characteristics, these profiles ensure that targeted therapies are selectively applied in delivering patient-centered care. A shining example of this has been the incorporation of trastuzumab for cancers that overexpress HER2, the use of